摘要
目的:观察多西紫杉醇(TAT)联合氟尿嘧啶(5-FU)及奥沙利铂(OXA)组成TFO方案治疗国人晚期胃癌的临床疗效及毒副反应。方法:50例晚期胃癌患者随机分为研究组及对照组。研究组25例给予TFO方案,对照组25例给予5-FU联合顺铂(PDD)组成的PF方案。每28天为1周期,至少2个周期后评价疗效。结果:全组可评价病例50例,疗效按RE-CIST标准评定,以CR+PR合计为有效,研究组中CR2例,PR11例,有效率52.0%;对照组中CR1例,PR3例,有效率16.0%,两组间疗效差异有显著性(P<0.05)。TFO方案主要毒副反应为Ⅰ～Ⅱ度为主的白细胞减少、脱发和胃肠道反应。结论:TFO方案治疗晚期胃癌疗效肯定,特别对初治者,毒副反应较轻,但有部分患者出现不同程度骨髓抑制,需集落刺激因子支持治疗。
Objective：To evaluate the clinical efficacy and toxicity of TFO regimen. TFO regimen consisted of taxotere（TAT） combined with 5-fluorouracil （5-FU） and oxaliplatin （OXA） in advanced gastric cancer. Methods：Total of 50 cases with advanced gastric cancer were involved in the study. For research group （25 cases）, the regimen of TFO was consisted of taxotere, received intravenous infusion of 25mg/m^2 in one hour at 1,8,15 day, fluorouracil, received intravenous infusion of 500mg/m^2 in 6 hours at 1,2,3,4, 5 day, oxaliplatin, received intravenous infusion of 70mg/m^2 in 3-4 hours at 1,8,15 day. For control group （25 cases）, was treated with 5-fluorouracil and oxaliplatin （PF） regimen. The same schedule for both groups waw repeated every 28 days,with two cycles for all patients. The efficacy for cases was evaluated by one month. Results： All 50 cases were evaluated. For research group, the total rate of efficacy was 52. 0%, including CR 2 cases and PR llcases. The total efficacy of control group was 16. 0%, including CR 2 cases and PR 3 cases. The difference of efficacy between the two groups was significant （P 〈 0. 05 ）. The main toxicity of TFO regimen included aleucocytosis, neutropenia, alopecia and gastrointestinal tract reaction. Conclusion：TFO regimen mentioned above was a considerable regimen for patients with advanced gastric cancer, specially for patients with firstly treatment. No severe side effects were observed, although bone marrow depression was occurred in some patients who needed support treatment with G-CSF.
出处
《临床肿瘤学杂志》
CAS
2007年第10期763-764,770,共3页
Chinese Clinical Oncology
